Algeria Approves Sino Biopharmaceutical's Adalimumab Biosimilar for Autoimmune Disease Treatment
Key Insights
Algeria's National Agency for Pharmaceutical Products (search) has approved an adalimumab biosimilar developed by Chia Tai Tianqing Pharmaceutical Group (search) (CTTQ), a subsidiary of China's Sino Biopharmaceutical.
The biosimilar targets autoimmune diseases including rheumatoid arthritis (search) and Crohn's disease (search), offering a more affordable alternative to the original Humira brand.
Algeria represents a strategic market for CTTQ's global biosimilar expansion, with the company planning to collaborate with local partners for commercialization.
Algeria's National Agency for Pharmaceutical Products (search) has granted market approval to Chia Tai Tianqing Pharmaceutical Group (search) (CTTQ) for its adalimumab biosimilar, marking a significant milestone in the Chinese company's international expansion strategy. The biosimilar targets autoimmune diseases including rheumatoid arthritis (search) and Crohn's disease (search), providing an alternative to the original biologic drug commonly sold under the brand name Humira.
Strategic Market Entry in North Africa
CTTQ, a Jiangsu province-based subsidiary of China's Sino Biopharmaceutical, identified Algeria as a key market in its global biosimilar expansion strategy. The North African nation, spanning nearly 2.4 million square kilometers with 47 million residents, represents Africa's largest country by land area. The company plans to collaborate with local partners to accelerate the commercialization process of its adalimumab biosimilar.
Biosimilars are highly similar to original biologic drugs but typically offer more affordable treatment options, entering the market after patents on the original products expire. The adalimumab biosimilar is used across a range of conditions to reduce inflammation in patients with autoimmune disorders.
Robust Regulatory Framework and Portfolio Expansion
China's National Medical Products Administration has strengthened its biosimilar approval process since 2015, implementing requirements for clinical trials to demonstrate comparable efficacy and ongoing safety monitoring. As of last year, China had approved more than 20 biosimilars, including CTTQ's adalimumab product.
CTTQ has developed a comprehensive biosimilar portfolio beyond adalimumab. The company markets bevacizumab for lung and kidney cancer (search), rituximab for blood cancers (search) and rheumatoid arthritis (search), and trastuzumab for breast cancer (search) in the Chinese market. Additionally, the firm has gained approval for its self-developed benmelstobart, which targets lung and womb cancers (search).
Manufacturing Excellence and Global Standards
The company operates large-scale research, development, and manufacturing facilities in Nanjing and Lianyungang, Jiangsu province. These production lines have achieved certification to standards set by both the European Union and the US Food and Drug Administration, demonstrating CTTQ's commitment to international quality standards and its capability to serve global markets.